NCT03999697 - A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions

Diffuse Large B Cell LymphomaFollicular LymphomaPrimary Cutaneous Follicle Centre LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueMantle Cell LymphomaPlasma Cell NeoplasmB Cell Lymphoma

Interventions

DRUG

Autologous chimeric antigen receptor T cell transfusing agent targeting CD22

The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy

Trial Locations (1)

230088

RECRUITING

PersonGen·Anke cellular therapeutics Co., Ltd, Hefei